Recombinant human histone H1.3
Alternative Names: OncoHist; Product F - SymbioTec; rhH1.3; SYN-20051504RU; SYN-20051604RULatest Information Update: 16 Apr 2021
Price :
$50 *
At a glance
- Originator SymbioTec
- Developer Dana-Farber Cancer Institute; Pharmsynthez; SymbioTec; Xenetic Biosciences
- Class Antineoplastics; Biological proteins; Recombinant proteins
- Mechanism of Action Apoptosis stimulants; Cell membrane modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Acute myeloid leukaemia; Non-Hodgkin's lymphoma
Most Recent Events
- 16 Apr 2021 Discontinued - Phase-I/II for Acute myeloid leukaemia in Germany (IV)
- 16 Apr 2021 Discontinued - Phase-II for Acute myeloid leukaemia (Combination therapy, Second-line therapy or greater) in Russia (IV)
- 16 Apr 2021 Discontinued - Phase-II for Non-Hodgkin's lymphoma (Second-line therapy or greater) in Russia (IV)